Beta Bionics Analyst Price Targets - Benzinga

SPY778.57+0.60%QQQ751.38+0.51%BTC/USD82,610.65+0.06%DIA516.21+0.89%GLD384.50+1.55%TLT77.97+0.12%

Beta Bionics Inc

BBNXNASDAQ

Trade with Public

Trade with Public

$17.63

0.201.15%

Last update: Oct 9, 4:00 PM

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2026 Benzinga | All Rights Reserved

Beta Bionics Analyst Price Targets - Benzinga

Beta Bionics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Beta Bionics (BBNX).

Price Target Range — 7 Quarters

Analyst Consensus — 14 Analysts

10Buy

4Hold

Consensus RatingBuy# Analysts14Avg. Consensus PT$25Upside to Avg. PT+41.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 24, 2026	Truist Securities	Richard Newitter	PT Raise	Buy	$23→$28
Sep 23, 2026	Wells Fargo	Larry Biegelsen	Initiate	Overweight	$28
Sep 15, 2026	B of A Securities	Travis Steed	PT Raise	Neutral	$18→$20
Sep 15, 2026	Truist Securities	Richard Newitter	PT Raise	Buy	$22→$23
Sep 15, 2026	Baird	Jeff Johnson	PT Raise	Neutral	$14→$16
Sep 14, 2026	Leerink Partners	Mike Kratky	PT Raise	Outperform	$24→$27
Aug 21, 2026	William Blair	Steven Lichtman	Initiate	Market Perform	—
Jul 28, 2026	UBS	Patrick Wood	Assumes	Buy	$22
Jul 15, 2026	Goldman Sachs	David Roman	PT Raise	Buy	$17→$19
Jul 13, 2026	Truist Securities	Richard Newitter	PT Raise	Buy	$18→$22
May 27, 2026	Goldman Sachs	David Roman	PT Cut	Buy	$19→$17
May 18, 2026	B of A Securities	Travis Steed	PT Cut	Neutral	$23→$11
Apr 22, 2026	Leerink Partners	Mike Kratky	PT Cut	Outperform	$25→$24
Apr 22, 2026	Stifel	Jonathan Block	PT Cut	Buy	$22→$20
Apr 15, 2026	Truist Securities	Richard Newitter	PT Cut	Buy	$25→$18
Apr 9, 2026	Goldman Sachs	David Roman	PT Cut	Buy	$23→$20
Feb 18, 2026	Stifel	Jonathan Block	PT Cut	Buy	$25→$22
Feb 18, 2026	Baird	Jeff Johnson	PT Cut	Neutral	$28→$14
Feb 4, 2026	Stifel	Jonathan Block	PT Cut	Buy	$31→$25
Feb 2, 2026	Truist Securities	Richard Newitter	PT Cut	Buy	$37→$25

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Truist Securities Maintains Buy on Beta Bionics, Raises Price Target to $28

Truist Securities analyst Richard Newitter maintains Beta Bionics (NASDAQ:BBNX) with a Buy and raises the price target from $23 to $28.

Benzinga Newsdesk

PRO
Wells Fargo Initiates Coverage On Beta Bionics with Overweight Rating, Announces Price Target of $28

Wells Fargo analyst Larry Biegelsen initiates coverage on Beta Bionics (NASDAQ:BBNX) with a Overweight rating and announces Price Target of $28.

Benzinga Newsdesk

PRO
Truist Securities Reiterates Buy on Beta Bionics, Raises Price Target to $23

Truist Securities analyst Richard Newitter reiterates Beta Bionics (NASDAQ:BBNX) with a Buy and raises the price target from $22 to $23.

Benzinga Newsdesk

PRO
Baird Maintains Neutral on Beta Bionics, Raises Price Target to $16

Baird analyst Jeff Johnson maintains Beta Bionics (NASDAQ:BBNX) with a Neutral and raises the price target from $14 to $16.

Benzinga Newsdesk

PRO
William Blair Initiates Coverage On Beta Bionics with Market Perform Rating

William Blair analyst Steven Lichtman initiates coverage on Beta Bionics (NASDAQ:BBNX) with a Market Perform rating.

Benzinga Newsdesk

Innovative Insulin Pumps Drive Optimism for Tandem, Beta Bionics

William Blair initiates coverage on Tandem Diabetes Care and Beta Bionics, highlighting their growth potential in the insulin pump market.

Vandana Singh